Benzodiazepine — Long-acting
Pregnancy: Avoid — fetal benzodiazepine syndrome (hypotonia, respiratory depression, withdrawal). If used near delivery: monitor neonate for days due to long half-life.
Clonazepam (Psychiatric Use)
Brand names: Rivotril
Adult dose
Dose: Panic disorder / anxiety (short-term adjunct): 0.5mg BD initially; increase by 0.5mg every 3 days to a maximum of 4mg daily. Bipolar disorder (acute mania adjunct): 1–2mg BD–TDS short-term. Epilepsy (myoclonic, absence): 0.5mg OD at night initially, increase to 4–8mg daily in divided doses.
Route: Oral
Frequency: Twice to three times daily
Max: 20mg daily (epilepsy — specialist only); 4mg daily (psychiatric indications)
Long-acting benzodiazepine (half-life 20–60h). Used short-term in psychiatry as an adjunct for acute mania (while mood stabiliser takes effect) or panic disorder. Significant dependence potential — limit to 2–4 weeks in psychiatric indications. Abrupt withdrawal after prolonged use can cause seizures — taper very slowly.
Paediatric dose
Dose: 0.01 mg/kg
Route: Oral
Frequency: Once to three times daily
Max: 0.05mg/kg/day (epilepsy)
BNFc: Epilepsy: 1 month–11 years: 10 micrograms/kg BD initially (max 500 micrograms BD); 12–17 years: 500 micrograms BD initially. Psychiatric use in children: seek specialist child and adolescent psychiatry opinion.
Dose adjustments
Renal
Use with caution — enhanced sedation in renal impairment.
Hepatic
Avoid in severe hepatic impairment — accumulation risk (long half-life and hepatic metabolism).
Paediatric weight-based calculator
BNFc: Epilepsy: 1 month–11 years: 10 micrograms/kg BD initially (max 500 micrograms BD); 12–17 years: 500 micrograms BD initially. Psychiatric use in children: seek specialist child and adolescent psychiatry opinion.
Clinical pearls
- Antidote: flumazenil 200 micrograms IV then 100 micrograms every 60 seconds (max 1mg) — note: flumazenil has a shorter half-life than clonazepam; repeated doses or infusion may be needed
- Withdrawal: long half-life means withdrawal symptoms are delayed (days after stopping) but withdrawal seizures can occur — taper over weeks to months for long-term users
- Paradoxical disinhibition: may worsen behaviour in borderline personality disorder — use with great caution in personality disorders; can precipitate rage or self-harm
- Not for long-term use in psychiatry — dependence develops rapidly; NICE recommends maximum 2–4 weeks for anxiety indications
Contraindications
- Respiratory failure
- Myasthenia gravis
- Sleep apnoea
- Acute angle-closure glaucoma
- Severe hepatic impairment
- Hypersensitivity to benzodiazepines
Side effects
- Sedation, cognitive impairment
- Ataxia, dizziness
- Behavioural disinhibition
- Dependence and withdrawal (severe — seizures on abrupt withdrawal)
- Paradoxical aggression (especially in personality disorders)
- Respiratory depression (particularly with opioids)
Interactions
- CNS depressants, opioids, alcohol — additive respiratory depression
- Valproate (with clonazepam in absence epilepsy) — may precipitate absence status — use with caution
- CYP3A4 inhibitors — increase clonazepam levels
Monitoring
- Dependence risk (review weekly in short-term use)
- Respiratory function
- Cognitive function (long-term — impairs memory)
- Withdrawal symptoms on dose reduction
Reference: BNFc; BNF 90; NICE CG185 (Bipolar Disorder); NICE CG22 (Anxiety). Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
- Corrected QT Interval (Bazett) · ECG
- Bazett Corrected QT Interval (QTc) Calculator · Arrhythmia
- Long QT Syndrome (Schwartz Score) · Channelopathy / Sudden Cardiac Death
- Benzodiazepine Conversion Calculator · Drug Conversion
- Withdrawal Assessment Tool (WAT-1) for Paediatric Iatrogenic Withdrawal · Critical Care
- CIWA-Ar — Alcohol Withdrawal Scale · Diagnosis
Pathways
- Acute Behavioural Disturbance / Rapid Tranquillisation · RCEM 2022; RCPsych 2022; NICE NG10
- Self-Harm Presentation · NICE NG225 (2022)
- Capacity Assessment (Mental Capacity Act) · MCA 2005; Code of Practice
- Acute Psychosis Management · NICE CG178 2014
- Depression Management · NICE CG90 2022
- Lithium Therapy Monitoring · NICE CG185 / BNF